
The Indian Express

The Financial Express

Latest News

EIW

Market Indicators

Screen

Boulevard India

Celebrity Chat

Express Computers

Express Power

Letters

Advertisers Forum




Business Forum



Express Properties

Palki - Travel & Tours

Information Technology

Astrosurf

Eco-India

Dr Know

Morning Digest

Express Greeting

Graffiti

Drumbeat: Ad Buzzaar
|

| |
Thursday, November 12, 1998
Drug-makers body cautions centre on product patents
Our Infrastructure Bureau
Mumbai, Nov 11: The Indian Drug Manufacturers' Association (IDMA) has cautioned the government against the serious implications of introducing the new product patent regime without adequate and effective legislative and administrative safeguards. IDMA has stressed the need to ensure the examination of patent claims for novelty, utility, subject matter and public opposition to the inventions in order "to eliminate undeserved, frivolous, fraudulent or excessive claims of matters of public domain as on January 1, 1995."Under the TRIPS agreement during the transition period up to 2005, five-year exclusive marketing rights should be given to a patent holder. However, experts say this proviso is vague and can be interpreted in numerous ways. "As India signed Gatt from January 1, 1995, anything prior to this date has to be considered as knowledge in public domain. Hence exclusive marketing rights cannot be applied to products unless they have a valid patent post January 1, 1995". Domestic firms also allege thatthere is considerable multinational pressure to claim exclusivity for products marketed by them for the first time post January 1, 1995. This, the domestic industry argues, is untenable, illegal and detrimental to both industry and consumers. IDMA has also urged the government to ensure that measures for licensing arrangements allowing production by local firms are in place. Copyright © 1998 Indian Express Newspapers (Bombay) Ltd.

Top
|
|
|






Printer-friendly page |
|